A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients

Figures & data

Table 1 Patient Demographics And Disease Characteristics

Variable	No. Of Cases (%)
Age, years
Median	55.6
Range	35–79
PS ECOG
0	1 (4.5%)
1	16 (72.7%)
2	4 (18.2%)
3	1 (4.5%)
Histologic type
Serous carcinoma	14 (63.6%)
Endometrioid carcinoma	2 (9.1%)
Clear cell carcinoma	4 (18.2%)
Not available	2 (9.1%)
Lines of prior anticancer therapy
1–3	6 (27.3%)
>3	16 (72.7%)
Prior therapy
Chemotherapy and surgery	19 (86.4%)
Surgery, radiotherapy and chemotherapy	3 (13.6%)

Note: All patients enrolled (n=22).

Figure 1 Trial profile.

Table 2 Summary Of Tumor Response

	Monotherapy, n (%)	Combined Treatment, n (%)	Total (%)
Complete response	0	0	0
Partial response	0	4 (33.3%)	4 (20%; 8–39.2)
Stable disease	5 (62.5%)	8 (66.7%)	13 (60%; 36.5–83.5)
Progressive disease	3 (37.5%)	0	3 (15%; –2.1–32.1)
Response rate (CR+PR+SD)	5 (62.5%)	12 (100%)	17 (85%; 67.9–100)

Notes: Data are n (%) and n (%; 95% CI). Two patients without post or baseline efficacy assessments were excluded.

Figure 2 Waterfall plot for the best percentage change in target lesion size.

Figure 3 Progression-free survival (A) and overall survival (B) of patients with treated by apatinib.

Figure 4 Progression-free survival (A) and overall survival (B) of patients received apatinib or apatinib combined with chemotherapy.

Table 3 Common Adverse Events And Clinical Laboratory Abnormalities

Adverse Event	Grade 1/2, n (%)		Grade 3/4, n (%)		Total, n (%)
Monotherapy	Combined Treatment	Monotherapy	Combined Treatment
Non-hematologic
Hypertension	2 (9.1%)	3 (13.6%)	2 (9.1%)	2 (9.1%)	9 (40.5%)
Mucositis	2 (9.1%)	2 (9.1%)	0	1 (4.5%)	5 (22.7%)
Fatigue	3 (13.6%)	3 (13.6%)	0	0	6 (27.2%)
Anorexia	3 (13.6%)	1 (4.5%)	1 (4.5%)	0	5 (22.7%)
Albuminuria	1 (4.5%)	5 (22.7%)	0	1 (4.5%)	7 (31.8%)
Hand foot syndrome	1 (4.5%)	2 (9.1%)	0	3 (13.6%)	6 (27.2%)
Hemorrhage	1 (4.5%)	2 (9.1%)	0	0	3 (13.6%)
Edema	1 (4.5%)	2 (9.1%)	0	0	3 (13.6%)
Cardiac failure	0	0	1 (4.5%)	0	1 (4.5%)
Hematologic
Hemoglobin	2 (9.1%)	0	0	0	2 (9.1%)
Leukocyte	1 (4.5%)	3 (13.6%)	0	1 (4.5%)	5 (22.7%)
Platelets	0	0	1 (4.5%)	1 (4.5%)	2 (9.1%)